Amgen Hopes Sentiment Swings Sweeter for Myeloma Drug at Key Blood Cancer Meeting
at The Street - Sat Dec 06, 10:00AM CST
Scientists and investors are getting their first detailed look this weekend at a large study of Amgen's multiple myeloma drug Kyprolis.
AMGN: 153.48 (+0.30), SNY: 49.42 (+0.82), CELG: 115.88 (+0.16)